20 results about "Genetically modified organism" patented technology

The invention relates to the field of gene engineering. In particular, the present invention relates to cytosine deaminases and their use in base editing. More specifically, the invention relates to a method for screening and identifying a deaminase, a base editing system based on a newly identified cytosine deaminase, a method for editing a target sequence in a genome of an organism (such as a plant) by using the base editing system, and a method for screening and identifying the target sequence. As well as genetically modified organisms (e.g., plants) and progeny thereof produced by the method.

The invention discloses application of SmCLE mature peptide in inhibiting plant aging, and belongs to the technical field of plant biology. The invention discloses application of a SmCLE mature peptide in inhibiting plant aging. The amino acid sequence of the SmCLE mature peptide is SEQ ID NO: 1. The CLE peptide is applied to the aspect of inhibiting plant aging, solves the problem that the existing CLE peptide cannot be applied to anti-aging of plants, especially medicinal plants or non-mode crops, has the advantages of small molecular weight, easiness in synthesis, low action concentration and good biocompatibility, can realize accurate regulation and control of leaf aging through exogenous application, and has a wide application prospect. And the safety problem of transgenic organisms is avoided.

This disclosure provides genetically engineered organisms with genetic modifications that are useful for producing desirable alkaloids. This disclosure also provides methods of making genetically engineered organisms that can produce desirable alkaloids. The organisms described herein produce alkaloids in amounts beyond that produced from comparable wild-type organisms. In certain embodiments, the genetically engineered organisms are fungi from the Basidiomycota division.

Provided is a computer implemented method for mapping transgene integration into n organism by providing a custom genome comprising a reference genome sequence and a transgene sequence, aligning sequence reads of the transgenic organism to the custom genome, identifying candidate junction reads, wherein the candidate junction reads correspond to sequence reads comprising sequence regions that align to the transgene sequence and to the host sequence, categorizing the candidate junction reads into junction clusters, wherein each of the junction clusters comprises a plurality of the candidate junction reads each with an alignment segment terminus within a cluster proximity region of the custom genome, determining a transgene junction based on the junction clusters that possesses at least three of the candidate junction reads within the cluster proximity region of the custom genome and mapping the integration of the transgene into the transgenic organism based on the transgene junctions.

Polynucleotides comprising genetic regulatory elements, as well as constructs, host cells, and transgenic organisms comprising the same are described. The polynucleotides can control the expression of an operably linked gene in a host cell or organism, such as a plant cell or a plant. Methods of using the polynucleotide to control the expression of an operably linked gene of interest in a plant or plant cell are further provided.

Described herein are recombinant proteins comprising a sequence at least at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO:1, 2, or 3; and a secretion signal sequence heterologous thereto. The disclosure also provides genetically engineered microorganisms and fermentation methods for the production of said recombinant proteins.

The invention relates to a Burkholderia sp.S3-7 strain, which is characterized in that the Burkholderia sp.S3-7 strain is preserved in Guangdong Microbial Culture Collection Center on July 15, 2025, the preservation number is GDMCC NO.66685, and the preservation address is the 5th floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou. The Burkholderia sp.S3-7 provided by the invention has relatively high degradation capacity and safety on collagen, can remarkably improve the yield of fish skin collagen peptide, does not have safety risks possibly brought by transgenic organisms, is high in public acceptability, is more suitable for being applied to the fields of food, health care products and the like, ensures the safety of the product and widens the application range of the product.

The present disclosure provides polypeptides having xanthan lyase activity, compositions, and uses thereof. The present disclosure also provides polynucleotides, expression vectors, host cells, and genetically modified organisms (e.g., bacteria) encoding xanthan lyases.

This invention relates to the field of genetic engineering. Specifically, it relates to cytosine deaminases and their use in base editing. More specifically, it relates to a method for screening and identifying deaminases, a base editing system based on newly identified cytosine deaminases, a method for base editing a target sequence in the genome of an organism (e.g., a plant) using this base editing system, and genetically modified organisms (e.g., plants) and their offspring produced by said method.

A biosynthetic method and composition for producing indigo dyes comprising indigotin and isatin. A tryptophanase (TRP) and a flavin monooxygenase (FMO) can be produced through a transgenic organism having carrier encoded tryptophanase and flavin monooxygenase. The produced tryptophanase and flavin monooxygenase convert L-tryptophan into indigo dyes in the presence of one or more bioactive additives selected from cysteine, 2-hydroxyindole, or 2-indoxyl, and the weight ratio of indigotin to isatin in the dyes is between 1:0.1 to 1:4. The dyes have a hue of X: 0.1920 to 0.2481, Y: 0.2537 to 0.2019, Z: 0.5543 to 0.5501 in the CIE XYZ color space definition. Selectable and repeatable dyeing hues are provided.

The present invention concerns the field of antibodies. More specifically, it relates to an antibody which specifically binds to a hapten being fentanyl or a derivative thereof, said antibody binding to the hapten with an equilibrium dissociation constant (Kd) of at most 1.000 pM, at most 800 pM, at most 600 pM, at most 400 pM, at most 200 pM, at most 100 pM or at most 75 pM, wherein the binding pocket for the hapten comprises amino acids from all three complementary determining regions (CDRs) of each chain. The present invention also relates to a polynucleotide encoding said antibody, a vector or expression construct comprising the poly-nucleotide, a host cell comprising the polynucleotide or the vector or expression construct or a non-human transgenic organism comprising said polynucleotide or said vector or expression construct. The invention also relates to said antibody or said polynucleotide for use as a medicament for treating and / or preventing a disease or condition in a subject associated with administration fentanyl or a derivative thereof.

This invention provides a waste treatment system that improves the efficiency of operating energy when processing materials, including genetically modified organisms. [Solution] The system comprises a manufacturing unit 10 that produces a target substance from raw plant material, an energy supply facility 50 that supplies manufacturing energy to the manufacturing unit 10, an inactivation device 20 into which a primary material A containing genetically modified organisms, etc., discharged as residue from the manufacturing unit 10 is introduced and the primary material A is heated at a first temperature to process it into a secondary material B in which the genetically modified organisms, etc., are inactivated, a methane fermentation device 30 which is a volume reduction device into which the secondary material B is introduced and the secondary material B is heated at a second temperature lower than the first temperature to reduce the volume of the secondary material B, a first pipe 61 that introduces the primary material A from the manufacturing unit 10 to the inactivation device 20, a second pipe 62 that introduces the secondary material B from the inactivation device 20 to the methane fermentation device 30, and a heat exchanger 40 located in the middle of the first pipe 61 and the second pipe 62.

This invention provides enzymes that promote the stable and / or intracellularly abundant synthesis of luciferin from precursor compounds, and the reduction of oxyluciferin to luciferin, as well as uses thereof. [Solution] A method for preparing compounds identical to fungal luciferin and preluciferin in vitro or in vivo is provided; an expression cassette comprising nucleic acids, vectors, and regulatory elements necessary for nucleic acid expression in selected host cells; further, a combination of nucleic acids for obtaining cells, stable cell lines, transgenic organisms (e.g., plants, animals, fungi, or microorganisms), autoluminescent cells, cell lines, or transgenic organisms containing nucleic acids, vectors, or expression cassettes; a combination of proteins for producing luciferin or its precursors from simpler compounds; and a kit comprising nucleic acids, vectors, or expression cassettes for producing luminescent cells, cell lines, or transgenic organisms.

Provided is a computer implemented method for mapping transgene integration into n organism by providing a custom genome comprising a reference genome sequence and a transgene sequence, aligning sequence reads of the transgenic organism to the custom genome, identifying candidate junction reads, wherein the candidate junction reads correspond to sequence reads comprising sequence regions that align to the transgene sequence and to the host sequence, categorizing the candidate junction reads into junction clusters, wherein each of the junction clusters comprises a plurality of the candidate junction reads each with an alignment segment terminus within a cluster proximity region of the custom genome, determining a transgene junction based on the junction clusters that possesses at least three of the candidate junction reads within the cluster proximity region of the custom genome and mapping the integration of the transgene into the transgenic organism based on the transgene junctions.

The present application belongs to the technical field of transgenic organism synthesis, and particularly relates to a novel MYB transcription factor for increasing anthocyanin content in plants. The SrMYB1 gene is isolated from Epigaea regina, and the SrMYB1 gene is constructed into an expression vector through genetic engineering technology, and a transgenic tobacco overexpressing the SrMYB1 gene is obtained by using an agrobacterium-mediated infection method. The transgenic tobacco overexpressing the SrMYB1 gene of the present application significantly accumulates anthocyanin in different tissues such as roots, stems, leaves, flowers, fruits and seeds, and is purple. The total anthocyanin content in the leaves of the transgenic tobacco of the present application is about 12.8 times that of wild-type tobacco. It is shown that the SrMYB1 gene isolated from Epigaea regina can be used to increase the anthocyanin content in tobacco, and provides more options for biosynthesis of anthocyanin, and has a good application prospect in biosynthesis of anthocyanin.

  42      Abstract  The present invention is directed to nucleic acid molecules which encode novel luciferases, functional fragments thereof, homologs and mutants, as well as to proteins encoded by said nucleic acids. The nucleic acid molecules of interest are isolated from fungi or obtained by genetic engineering methods. Also, host cells, stable cell lines and transgenic organisms comprising said nucleic acid molecules are provided. In addition, antibodies specific to the proteins of the present invention are provided. Said proteins and nucleic acids are used in many applications and methods, in particular, in labelling organisms, cells, cellular organelles, or proteins. Also, said protein and nucleotide compositions are used in methods for detecting protein-protein interactions, for testing promoter activity under various conditions. Finally, provided are kits for the use of proteins and nucleic acids of the present invention in the diversity of methods and applications. Abstract The present invention is directed to nucleic acid molecules which encode novel luciferases, functional fragments thereof, homologs and mutants, as well as to proteins encoded by said nucleic acids. The nucleic acid molecules of interest are isolated from fungi or obtained by genetic engineering methods. Also, host cells, stable cell lines and transgenic organisms comprising said nucleic acid molecules are provided. In addition, antibodies specific to the proteins of the present invention are provided. Said proteins and nucleic acids are used in many applications and methods, in particular, in labelling organisms, cells, cellular organelles, or proteins. Also, said protein and nucleotide compositions are used in methods for detecting protein-protein interactions, for testing promoter activity under various conditions. Finally, provided are kits for the use of proteins and nucleic acids of the present invention in the diversity of methods and applications. 42 20 24 20 33 78 21 M ay 2 02 4 A b s t r a c t 2 0 2 4 2 0 3 3 7 8 2 1 M a y 2 0 2 4

A prebiotic and probiotic sandwich cookie is described. The prebiotic and probiotic sandwich cookie includes at least two biscuits and a crème filing sandwiched between two of the at least two biscuits. Each of the at least two biscuits includes a polyphenol, a resistant starch, and a prebiotic soluble fiber. The crème filling comprises another resistant starch, a vegetable fat, and spores of a probiotic bacterium. The prebiotic and probiotic sandwich cookie and the crème filing fails to contain refined sugars, synthetic vitamins, genetically modified organisms (GMOs), artificial sweeteners, and artificial preservatives. Consumption of the prebiotic and probiotic sandwich cookie increases at least one of Lactobacillus bulgaricus, Bacillus coagulans, Collinsella aerofaciens, Hippurate, Erysipelotrichia, and Streptophyta in a consumer.

This invention provides a strain of Akkermansia myxophilus ( Akkermansia muciniphila The present invention provides a probiotic preparation comprising the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA). The Akkermansia myxophilus or its post-genetically modified organism (PGA) of the present invention can improve vascular endothelial cell function, increase testosterone secretion, and thus improve erectile dysfunction and reproductive capacity. The probiotic preparation of the present invention may comprise the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA) and yohimbine. This preparation can improve erectile dysfunction caused by vascular endothelial dysfunction, improve reproductive function in aged mice, and the components in this preparation have a synergistic effect.

A method of producing a plurality of proteins; it includes providing a transgenic organism with cells that have been modified to yield an alternatively spliced cassette section that has transgenes of interest at locations of spliced alternates that are separated by intronic sequences; and purifying proteins of interest expressed by the transgenes of interest in the transgenic organism following mutually exclusive splicing, thereby resulting in the plurality of proteins composed of the purified proteins of interest, and wherein the transgenic organism is an arthropod.